The Comparison of Good Clinical Examination (GCE) and Vibration Perception Threshold (VPT) In Diagnosis of Diabetic Sensory Neuropathy
Article Sidebar
Main Article Content
Abstract
Background: Diabetic neuropathy is one of the most common complications of diabetes, resulting from damaged nerves near the extremities and carrying clinical implications in terms of several morbidities. Prompt and accurate diagnosis is essential for effective management and prevention.
Objective: To compare the diagnostic accuracy of Good Clinical Examination (GCE) and Vibration Perception Threshold (VPT) in diabetic sensory neuropathy.
Methods: A cross-sectional study was conducted at the Department of Endocrinology, Hayatabad Medical Complex, Peshawar, from May 2023 to April 2024. A total of 120 patients with diabetes mellitus were enrolled. All participants underwent a complete clinical examination for symptoms suggestive of neuropathy, reflexes, and sensory tests according to GCE. Additionally, VPT measurements were recorded at various points on the body, including the medial malleolus, using a biothesiometer. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for both diagnostic methods. Statistical analysis was performed using SPSS software version 25.0, and receiver operating characteristic (ROC) curves were used to evaluate diagnostic accuracy.
Results: The mean age of participants was 56.3 ± 12.4 years. The sensitivity, specificity, PPV, and NPV of GCE for diagnosing diabetic sensory neuropathy were 75.0%, 85.0%, 70.0%, and 88.0%, respectively. For VPT, these values were 90.0%, 80.0%, 83.0%, and 88.0%, respectively. Combining GCE and VPT resulted in a sensitivity of 92%, specificity of 88%, PPV of 85%, and NPV of 90%.
Conclusion: Both GCE and VPT are useful in diagnosing diabetic sensory neuropathy, but their combination improves diagnostic accuracy. The integrated use of GCE and VPT is recommended for comprehensive and reliable diagnosis.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic Neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747-787.
Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.
Boulton AJM, Armstrong DG, Kirsner RS, Attinger CE, Lavery LA, Lipsky BA, et al. Diagnosis and Management of Diabetic Foot Complications. Diabetes Care. 2008;31(8):1679-1685.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33(10):2285-2293.
American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2005;28(1).
Perkins BA, Olaleye D, Zinman B, Bril V. Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care. 2001;24(2):250-256.
Herman WH, Kennedy L, Goenka N. The American Diabetes Association Diabetes Research Perspective. Diabetes Care. 2005;28(6):1642-1649.
England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal Symmetrical Polyneuropathy: A Definition for Clinical Research. Neurology. 2005;64(2):199-207.
Novella SP, Inman RD, Barrett MJ. Simple Office-Based Detection of Peripheral Neuropathy in the Elderly. Arch Intern Med. 1992;152(2):313-316.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A Multicenter Study of the Prevalence of Diabetic Peripheral Neuropathy in the United Kingdom Hospital Clinic Population. Diabetologia. 1993;36(2):150-154.
Davies M, Brophy S, Williams R, Taylor A. The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care. 2006;29(7):1518-1522.
Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and Neuropathological Criteria for the Diagnosis and Staging of Diabetic Polyneuropathy. Brain. 1986;109(5):861-880.
Young MJ, Veves A, Smith AC, Walker MG, Boulton AJ. Restoring Lower Limb Sensation in Diabetic Patients: A Double-Blind Placebo-Controlled Study of Two Months’ Treatment with Alprostadil. Diabetologia. 1994;37(4):359-364.
Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. The North-West Diabetes Foot Care Study: Incidence of, and Risk Factors for, New Diabetic Foot Ulceration in a Community-Based Patient Cohort. Diabet Med. 2002;19(5):377-384.
Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care. 2002;25(11):2048-2052.
Brown MJ, Asbury AK, Diers D, et al. Diabetic Peripheral Neuropathy: Pitfalls in Testing and the Utility of Screening. Diabetes Metab Res Rev. 2004;20(S1).
Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive Foot Care in People with Diabetes. Diabetes Care. 1998;21(12):2161-2177.
Djankpa FT, Amoah AG, Adzaku FK, Aidoo E, Boateng I. Assessing the vibration perception threshold in a community sample of adult Ghanaians. Plos one. 2023 Nov 8;18(11):e0291606.
Sharma K. N S, Kumar H A. Assessment of the diagnostic accuracy of Vibrasense compared to a biothesiometer and nerve conduction study for screening diabetic peripheral neuropathy. Journal of Foot and Ankle Research. 2023 Sep 28;16(1):65.
Prinyakupt J, Yootho T. A Design and Construction of the Vibration Perception Threshold Measurement Device for Diabetes. International Journal of Online & Biomedical Engineering. 2024 Jul 1;20(7).